Wei Phin Tan1, Ahmed ElShafei2, Alireza Aminsharifi1, Ahmad O Khalifa3, Thomas J Polascik4. 1. Division of Urology, Department of Surgery, Duke University Medical Center, Durham, NC. 2. Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH; Department of Urology, Medical School, Cairo University, Cairo, Egypt. 3. Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH; Department of Urology, Menoufia University, Shebin Al Kom, Egypt. 4. Division of Urology, Department of Surgery, Duke University Medical Center, Durham, NC. Electronic address: thomas.polascik@duke.edu.
Abstract
BACKGROUND: We compared the short-term oncologic and functional outcomes of salvage focal cryotherapy (SFC) with those of salvage total cryotherapy (STC) for radiotherapy (RT)-persistent/recurrent prostate cancer. MATERIALS AND METHODS: We queried the Cryo On-Line Database registry for men who had undergone SFC and STC of the prostate for RT-persistent or recurrent disease. Propensity score weighting was used to match age at treatment, presalvage therapy prostate-specific antigen level, Gleason sum, and presalvage cryotherapy androgen deprivation therapy status. The primary outcome was progression-free survival. RESULTS: A total of 385 men with biopsy-proven persistent or recurrent prostate cancer after primary RT were included in the present study. The median follow-up, age, prostate-specific antigen, and Gleason sum before salvage cryotherapy was 24.4 months (first and third quartile, 9.8 and 60.3), 70 years (first and third quartile, 66 and 74 years), 4 ng/dL (first and third quartile, 2.7 and 5.6 ng/dL), and 7 (first and third quartile, 6 and 8), respectively. After propensity score weighting, the difference in progression-free survival was not statistically significant between the patients who had undergone STC and those who had undergone SFC (79.8% vs. 76.98%; P = .11 on weighted log-rank test). SFC was associated with a lower probability of post-treatment transient urinary retention (5.6% vs. 22.4%; P < .001). No significant differences were found in the incidence of rectal fistula (1.4% vs. 3.8; P = .30), new-onset urinary incontinence within 12 months (9.3% vs. 15.1%; P = .19), or new-onset erectile dysfunction within 12 months (52.6% vs. 59.6%; P = .47) between the SFC and STC groups, respectively. CONCLUSIONS: STC resulted in similar 2-year oncologic outcomes compared with SFC in the RT-persistent/recurrent disease population. However, the patients who had undergone SFC had a lower urinary retention rate compared with those who had undergone STC.
BACKGROUND: We compared the short-term oncologic and functional outcomes of salvage focal cryotherapy (SFC) with those of salvage total cryotherapy (STC) for radiotherapy (RT)-persistent/recurrent prostate cancer. MATERIALS AND METHODS: We queried the Cryo On-Line Database registry for men who had undergone SFC and STC of the prostate for RT-persistent or recurrent disease. Propensity score weighting was used to match age at treatment, presalvage therapy prostate-specific antigen level, Gleason sum, and presalvage cryotherapy androgen deprivation therapy status. The primary outcome was progression-free survival. RESULTS: A total of 385 men with biopsy-proven persistent or recurrent prostate cancer after primary RT were included in the present study. The median follow-up, age, prostate-specific antigen, and Gleason sum before salvage cryotherapy was 24.4 months (first and third quartile, 9.8 and 60.3), 70 years (first and third quartile, 66 and 74 years), 4 ng/dL (first and third quartile, 2.7 and 5.6 ng/dL), and 7 (first and third quartile, 6 and 8), respectively. After propensity score weighting, the difference in progression-free survival was not statistically significant between the patients who had undergone STC and those who had undergone SFC (79.8% vs. 76.98%; P = .11 on weighted log-rank test). SFC was associated with a lower probability of post-treatment transient urinary retention (5.6% vs. 22.4%; P < .001). No significant differences were found in the incidence of rectal fistula (1.4% vs. 3.8; P = .30), new-onset urinary incontinence within 12 months (9.3% vs. 15.1%; P = .19), or new-onset erectile dysfunction within 12 months (52.6% vs. 59.6%; P = .47) between the SFC and STC groups, respectively. CONCLUSIONS:STC resulted in similar 2-year oncologic outcomes compared with SFC in the RT-persistent/recurrent disease population. However, the patients who had undergone SFC had a lower urinary retention rate compared with those who had undergone STC.
Authors: H M Sandler; R L Dunn; P W McLaughlin; J A Hayman; M A Sullivan; J M Taylor Journal: Int J Radiat Oncol Biol Phys Date: 2000-10-01 Impact factor: 7.038
Authors: Mack Roach; Gerald Hanks; Howard Thames; Paul Schellhammer; William U Shipley; Gerald H Sokol; Howard Sandler Journal: Int J Radiat Oncol Biol Phys Date: 2006-07-15 Impact factor: 7.038
Authors: Andre Luis de Castro Abreu; Duke Bahn; Scott Leslie; Sunao Shoji; Paul Silverman; Mihir M Desai; Inderbir S Gill; Osamu Ukimura Journal: BJU Int Date: 2013-08 Impact factor: 5.588
Authors: Yong-Hong Li; Ahmed Elshafei; Gautum Agarwal; Herbert Ruckle; Julio Powsang; J Stephen Jones Journal: Prostate Date: 2014-10-04 Impact factor: 4.104
Authors: Hashim Uddin Ahmed; Paul Cathcart; Neil McCartan; Alex Kirkham; Clare Allen; Alex Freeman; Mark Emberton Journal: Cancer Date: 2012-01-03 Impact factor: 6.860
Authors: Martin T King; David D Yang; Anthony V D'Amico; Ivan Buzurovic; Thomas C Harris; Christian V Guthier; Graeme S Steele; Martin N Kathrins; Atish D Choudhury Journal: Front Oncol Date: 2022-09-29 Impact factor: 5.738
Authors: Wei Phin Tan; Ardeshir R Rastinehad; Laurence Klotz; Peter R Carroll; Mark Emberton; John F Feller; Arvin K George; Inderbir S Gill; Rajan T Gupta; Aaron E Katz; Amir H Lebastchi; Leonard S Marks; Giancarlo Marra; Peter A Pinto; Daniel Y Song; Abhinav Sidana; John F Ward; Rafael Sanchez-Salas; Jean de la Rosette; Thomas J Polascik Journal: Urol Oncol Date: 2021-03-04 Impact factor: 3.498
Authors: Thomas Willigenburg; Marieke J van Son; Sandrine M G van de Pol; Wietse S C Eppinga; Jan J W Lagendijk; Hans C J de Boer; Marinus A Moerland; Jochem R N van der Voort van Zyp; Max Peters Journal: Clin Transl Radiat Oncol Date: 2021-06-29